Aytu Biopharma (AYTU) Net Income Growth (3y) (2014 - 2026)
Powered by 
Analysis
Aytu Biopharma (AYTU) Net Income Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | 2.47% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 39.28% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | 19.14% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -28.09% |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | -6.82% |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | 42.23% |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | 8.71% |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | 7.94% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 7.94% |
| Dec 31, 2025 | -16.50% |
| Sep 30, 2025 | 68.72% |
| Jun 30, 2025 | -63.47% |
| Mar 31, 2025 | 27.55% |
| Dec 31, 2024 | 27.44% |
| Sep 30, 2024 | 27.09% |
| Jun 30, 2024 | 74.91% |
| Dec 31, 2023 | 70.68% |
| Sep 30, 2023 | -23.55% |
| Jun 30, 2023 | 28.85% |
| Mar 31, 2023 | -7.04% |
| Dec 31, 2022 | -4.52% |
| Sep 30, 2022 | 47.81% |
| Jun 30, 2022 | 51.48% |
| Mar 31, 2022 | -128.05% |
| Dec 31, 2021 | -35.15% |
| Sep 30, 2021 | -99.76% |
| Jun 30, 2021 | -67.27% |
| Dec 31, 2020 | -31.48% |